Combination Chemotherapy for Advanced Colorectal Cancer
Author Information
Author(s): Mason M, Johnson P, Rudd R
Primary Institution: Velindre Hospital
Conclusion
The FOCUS trial remains valid and patients are not being disadvantaged based on current evidence.
Supporting Evidence
- The DMEC reported no safety or ethical reasons to close or change the trial.
- The current overall median survival for patients in the FOCUS trial is 16 months.
- Combination chemotherapy has shown significant survival benefits in other trials.
Takeaway
Doctors are studying how to best use combination chemotherapy for patients with advanced colorectal cancer, and they believe the current trial is still important.
Methodology
The FOCUS trial is a five-arm study assessing different chemotherapy combinations for colorectal cancer.
Potential Biases
Concerns were raised about the ethical implications of the trial's design and the impact of external studies.
Limitations
The trial's design may be affected by external evidence and the asymmetry in treatment crossover options.
Participant Demographics
Patients with advanced colorectal cancer, with 1006 participants enrolled at the time of the DMEC report.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website